BACKGROUND: Multimodality treatment has dramatically improved the outcome of @entity1 with @entity2828 . However, there appears to be little information concerning treatment-related complications in @entity1 who are long-term survivors. METHODS: Forty-one @entity1 with @entity2828 who were treated between 1960-1980 and who survived the disease by at least 20 years were included in the current study. In a retrospective analysis, all complications related to the multimodality treatment of @entity2828 were assessed. RESULTS: The @entity1 group was comprised of 17 @entity1 and 24 @entity1 , with a mean age at the time of presentation of 16.8 years (range, 5-51 years). Approximately 20% of the lesions were located in the pelvis. All but 9 @entity1 (78%) received chemotherapy as part of their treatment. The overall follow-up period averaged 25 years (range, 20-36 years). All except 1 @entity1 were alive at the time of final follow-up, with the latter @entity1 dying of radiation-induced secondary malignancy after 33 years. Only 17 @entity1 (41%) were found to be free of any complication. These included @entity3 , local recurrence, @entity5 , @entity174 , and radiation-associated and chemotherapy-associated morbidities. CONCLUSIONS: Although the @entity1 in the current study were treated successfully in terms of surviving an aggressive @entity5 , the high complication rate in this group of long-term survivors is noteworthy and indicates that long-term follow-up should be mandatory.

Complications in long-term survivors of XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men'] @entity2828 :: ('MESH:D012512', 'Disease') :: ['Ewing sarcoma'] @entity174 :: ('MESH:D050723', 'Disease') :: ['pathologic fractures'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'secondary malignancies'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity2828 :: (MESH:D012512,Disease) :: ['Ewing sarcoma']
